On the other hand, it was recently reported that specific antibodies directed against OPN are produced in the context of diseases associated with systemic inflammation (e.g., multiple sclerosis and experimental autoimmune encephalomyelitis) and might neutralize the effect of elevated OPN levels [22]. Here, SPP1 is linked to multiple sclerosis.